Nektar Therapeutics: A Dance of Hope and Hype

Nektar’s rezpegaldesleukin, a promising contender in the battle against alopecia areata and atopic dermatitis, has been graced with not one but two fast-track designations from the U.S. Food and Drug Administration (FDA). The first came in February for atopic dermatitis, and the second arrived like an encore at the end of July for severe to very severe alopecia areata. One might say the FDA has taken quite a shine to Nektar’s wares, though whether the market will follow suit remains to be seen.







